| Patent Number |
Title Of Patent |
Date Issued |
| 7427485 |
Method for classification of anti-psychotic drugs |
September 23, 2008 |
| The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti- |
| 7320785 |
Compositions and methods for modulation of DARPP-32 phosphorylation |
January 22, 2008 |
| The present invention provides methods and compositions for modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), cyclin- |
| 7129073 |
Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
October 31, 2006 |
| The present invention provides methods and compositions for modulating the activities of metabotropic glutamate receptor intracellular signaling molecules. The present invention provides methods and compositions for modulating the activities of casein kinase I and/or cyclin-dependent |
| 6989362 |
Methods of treating dopamine dysregulation using agents that regulate phosphorylation/dephosphor |
January 24, 2006 |
| The present invention discloses that DARPP-32 is substrate for the cyclin dependent kinase Cdk5. The phosphorylation takes place at a specific threonine residue of DARPP-32 (Threonine 75). The Cdk5 catalyzed phosphorylation of DARPP-32 converts this protein into an inhibitor of the c |
| 6444201 |
Treatment of alzheimer disease by modulation of synapsins |
September 3, 2002 |
| The role of synapsin II in both the reformation and the maintenance of synaptic connections in cultured hippocampal neurons can be the basis of therapy for neurodegenerative disorder, particularly Alzheimer disease, which involve the disruption of synapses. When synapsin II expression in |
| 6429010 |
DNA encoding the human synapsin III gene and uses thereof |
August 6, 2002 |
| A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. Furthermore, isoforms of synapsin III, e.g., synapsin IIIa, IIIb and IIIc, and have isolated and characterized, and cDNA encoding these isoforms has also bee |
| 6040168 |
DNA encoding the human synapsin III gene and uses thereof |
March 21, 2000 |
| A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. The synapsin III gene is located on human chromosome 22, in the vicinity of a region previously identified as a susceptibility locus for schizophrenia. The |
| 6013621 |
Method of treating psychosis and/or hyperactivity |
January 11, 2000 |
| The present invention discloses the bidirectional regulation of DARPP-32 phosphorylation by dopamine and dopamine D1 and D2 receptors. This disclosure leads to new methodology in the treatment of schizophrenia and related disorders. In addition, the present invention provides methods for |
| 5928882 |
Treatment and prevention of neurodegenerative diseases using modulators of Fe65 |
July 27, 1999 |
| Modulators of the protein Fe65 can be utilized to affect the interaction of the protein Fe65 with the cytoplasmic domain of amyloid precursor protein and thus provide therapeutics for the treatment and/or prevention of neurodegenerative diseases, such as Alzheimer's disease and dementia. |
| 5777195 |
Knockout mutant mouse for DARPP-32 and use thereof |
July 7, 1998 |
| A knockout mouse containing a non-functional allele for the gene that naturally encodes and expresses functional DARPP-32 is disclosed. This mouse contains two non-functional alleles for the gene that naturally encodes and expresses functional DARPP-32, and therefore is unable to exp |
| 5538983 |
Method of treating amyloidosis by modulation of calcium |
July 23, 1996 |
| Various first messengers linked to phospholipase C, including acetylcholine and interleukin-1, regulate the production both of the secreted form of the amyloid protein precursor and of amyloid .beta.-protein. Intracellular signals which are responsible for mediating these effects have no |
| 5385915 |
Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphory |
January 31, 1995 |
| A method of regulating phosphorylation of proteins involved in controlling processing or function of key proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques associated with Alzheimer disease comprising introducing an effective amount of a kinase |
| 5348963 |
Method of screening for modulators of amyloid formation |
September 20, 1994 |
| Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and |
| 5242932 |
Treatment of amyloidosis associated with Alzheimer disease |
September 7, 1993 |
| Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and |
| 4874694 |
Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders |
October 17, 1989 |
| A diagnostic method for neurological and psychiatric disorders utilizes the cerebrospinal fluid incubated in the presence of 32-P labelled ATP and an appropriate protein kinase. After termination of the reaction, a sample is applied to gels for electrophoresis. Subsequent autoradiography |
